Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Mar 15:9:30.
doi: 10.21037/tgh-23-104. eCollection 2024.

Revamping hepatitis C global eradication efforts: towards simplified and enhanced screening, prevention, and treatment

Calvin Q Pan  1   2 , James S Park  3   4   5
Affiliations
Editorial

Revamping hepatitis C global eradication efforts: towards simplified and enhanced screening, prevention, and treatment

Calvin Q Pan et al. Transl Gastroenterol Hepatol. .
No abstract available

Keywords: 30 direct-acting antivirals (30 DAAs); HCV management; Hepatitis elimination; adherence to therapy; hepatitis C virus care cascade (HCV care cascade).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://tgh.amegroups.com/article/view/10.21037/tgh-23-104/coif). C.Q.P. received the institutional research grant from Gilead Sciences, Inc., and he is the Chair of the Hepatitis B Special Interest Group and the AASLD Hepatitis B Practice Guideline Writing Group for 2024. The other author has no conflicts of interest to declare.

Figures

Figure 1
Figure 1
HCV treatment algorithm from IDSA. *, a simplified treatment candidate: acute or chronic HCV individual with HCV treatment-naïve status (without cirrhosis or with compensated cirrhosis). IDSA, Infectious Disease Society of America; HCV, hepatitis C virus; Gle/Pib, glecaprevir/pibrentasvir; Sof/Vel, sofosbuvir/velpatasvir; SVR12, sustained virologic response 12 weeks after stopping antiviral therapy; RBV, weight-based ribavirin; GT3, genotype 3; NS5A, hepatitis C virus nonstructural protein 5A; RAS, resistance-associated substitution; h/o, history of; Sof/Vel/Vox, sofosbuvir/velpatasvir/voxilaprevir; Gle/Pib/Sof, glecaprevir/pibrentasvir/sofosbuvir.
Figure 2
Figure 2
Algorithm for the management of nonadherence to HCV therapy. HCV, hepatitis C virus; Gle/Pib, glecaprevir/pibrentasvir; Sof/Vel/Vox, sofosbuvir/velpatasvir/voxilaprevir; Sof/Vel, sofosbuvir/velpatasvir; RBV, weight-based ribavirin; GT3, genotype 3; NS5A, hepatitis C virus nonstructural protein 5A; RAS, resistance-associated substitution; Gle/Pib/Sof, glecaprevir/pibrentasvir/sofosbuvir.
See this image and copyright information in PMC

Comment on

References

    1. World Health Organization. Global health sector strategy on viral hepatitis, 2016-2021. 2016. Accessed October 30th, 2023. Available online: https://apps.who.int/iris/bitstream/handle/10665/246177/WHO-HIV-2016.06-...
    1. Suryaprasad AG, White JZ, Xu F, et al. Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006-2012. Clin Infect Dis 2014;59:1411-9. 10.1093/cid/ciu643 - DOI - PubMed
    1. Akyar E, Seneca KH, Akyar S, et al. Linkage to Care for Suburban Heroin Users with Hepatitis C Virus Infection, New Jersey, USA. Emerg Infect Dis 2016;22:907-9. 10.3201/eid2205.151980 - DOI - PMC - PubMed
    1. Kaufman HW, Bull-Otterson L, Meyer WA, 3rd, et al. Decreases in Hepatitis C Testing and Treatment During the COVID-19 Pandemic. Am J Prev Med 2021;61:369-76. 10.1016/j.amepre.2021.03.011 - DOI - PMC - PubMed
    1. Bhattacharya D, Aronsohn A, Price J, et al. Hepatitis C Guidance 2023 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Clin Infect Dis 2023;ciad319. 10.1093/cid/ciad319 - DOI - PubMed